MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
3.200
+0.260
+8.84%
After Hours: 3.198 -0.002 -0.05% 19:45 04/13 EDT
OPEN
2.910
PREV CLOSE
2.940
HIGH
3.260
LOW
2.890
VOLUME
2.39M
TURNOVER
--
52 WEEK HIGH
4.537
52 WEEK LOW
1.180
MARKET CAP
313.19M
P/E (TTM)
-1.7742
1D
5D
1M
3M
1Y
5Y
1D
Editas Medicine price target raised to $15 from $13 at Evercore ISI
TipRanks · 14h ago
Weekly Report: what happened at EDIT last week (0406-0410)?
Weekly Report · 19h ago
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
NASDAQ · 5d ago
Editas Medicine replaces Ernst & Young with PwC as auditor for 2026
Reuters · 6d ago
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
NASDAQ · 6d ago
JonesTrading Sticks to Their Buy Rating for Editas Medicine (EDIT)
TipRanks · 04/06 20:45
Weekly Report: what happened at EDIT last week (0330-0403)?
Weekly Report · 04/06 09:09
CRISPR Therapeutics: The Fundamental Standard-Bearer in a Fractured Genomic Sector
Barchart · 03/31 07:07
More
About EDIT
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.